Abstract: A unique four-solvent system comprising methanol, dimethylformamide, methylene chloride and water is employed to provide an improved process for the purification and crystallization of amphotericin B.

Abstract: A layer of plastic, either in film or coating form, is bonded to a sheet of non-woven material to form a base. When film is used, it is preferably smaller in size than the non-woven material and affixed to the top surface thereof by an acrylic adhesive. The plastic film is coated, on its exposed surface, with a layer of acrylic adhesive. When the plastic is in the form of a coating, it is bonded to the bottom surface of the non-woven material. A superabsorbent pad, smaller in size than the base, is wrapped in non-woven material and affixed to the base by the exposed adhesive layer. The remaining portion of the exposed adhesive layer forms a border around the superabsorbent pad for adhering the bandage to the skin.

Abstract: A method is provided for preventing or reducing deep vein thrombosis and/or pulmonary embolism by administering a thromboxane A.sub.2 receptor antagonist in conjunction with heparin. A combination of thromboxane A.sub.2 receptor antagonist and heparin is also provided.

Abstract: A process is provided for preparing phosphonyloxyacylamino acids and derivatives thereof having the structure ##STR1## wherein X is ##STR2## which includes the steps of treating a phosphonic acid dichloride of the structure ##STR3## with an .alpha.-hydroxy acid of the structure ##STR4## in the presence of base such as triethylamine at reduced temperatures to form the cyclic mixed anhydride of the structure ##STR5## (which is a new intermediate) and reacting the cyclic mixed anhydride with an amino acid or ester of the structureHXin the presence of base such as triethylamine produces the ACE inhibitor compound ##STR6## In an alternative process, the cyclic anhydride is quenched with water to form the diacid ##STR7## which is treated with a condensing agent such as dicyclohexyl carbodiimide (DCC), 1,1-carbonyldiimidazole (CDI) or thionyl chloride followed by quenching with the amino acidHXproduces the above ACE inhibitor compound.

Abstract: Pouch faceplate connecting rings have adhesive annular base layers with cover layers. Each cover layer has an annular portion covering the base layer and a radially extending gripping portion with a radially extending edge and a circumferentially extending tapering edge. The gripping portions are annularly offset to facilitate removal of the cover layers.

Abstract: In accordance with the present invention, new hydroxamic acid derivatives useful as .DELTA..sup.5 -lipoxygenase inhibitors are provided. These new compounds have the general formula ##STR1## wherein ##STR2## are cycloalkyl groups which may be the same or different; R is hydrogen, lower alkyl, aryl, lower alkenyl, cycloalkyl or aralkyl; n is an integer from 3 to 12; and m is an integer from 3 to 12. Further in accordance with the present invention, a method for using the above compounds is provided.

Abstract: An improved process for making compounds having the formula ##STR1## includes subjecting an intermediate of the formula ##STR2## to hydrogenolysis in the presence of a ketonic solvent so as to simultaneously remove both Z-protecting groups from compound II while selectively reprotecting the --A.sub.1 --NH.sub.2 end of that molecule.

Abstract: Hypotensive activity is exhibited by compounds having the formulas ##STR1##

Abstract: Compounds of the formula ##STR1## are disclosed wherein R.sub.1 is N-heterocyclic moiety. These compounds intervene in the conversion of angiotensin to angiotensin II by inhibiting renin and thus are useful as antihypertensive agents.

Abstract: Metal-chelating liquids having the formula ##STR1## wherein Y is oxygen or ##STR2## R.sub.

Abstract: In accordance with the present invention an improved process for preparing resolved compounds of the formula ##STR1## being the cis(+) isomer, is disclosed, wherein R.sub.1 and R.sub.2 are each independently hydrogen, halogen, alkyl, alkoxy, aryloxy, arylalkoxy, diarylalkoxy, arylalkyl, cyano, hydroxy, alkanoyloxy, ##STR2## fluoro substituted alkoxy, fluoro substituted alkyl, (cycloalkyl)alkoxy --NO.sub.2, NX.sub.3 X.sub.4, --S(O).sub.m alkyl, ##STR3## m is 0, 1 or 2; X.sub.1 and X.sub.2 are each independently hydrogen, alkyl, aryl or heteroaryl, or X.sub.1 and X.sub.2 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl or morpholinyl;X.sub.3 and X.sub.4 are each independently hydrogen, alkyl, alkanoyl, arylcarbonyl, heteroarylcarbonyl, or ##STR4## X.sub.5 is hydroxy, alkoxy, aryloxy, amino, alkylamino or dialkylamino; andX.sub.6 is alkyl, alkoxy or aryloxy; with the proviso that if R.sub.4 is a 7-alkyl group, it must have a tertiary carbon atom bonded to the ring.

Abstract: Compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein R.sub.4 is aryl are disclosed. These novel compounds are useful, for example, as cardiovascular agents.

Abstract: A method is provided for preparing phosphinic acid compounds, which are useful in preparing certain angiotensin converting enzyme inhibitors, which have the formula ##STR1## wherein R.sub.1 is lower alkyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl;R.sub.2 is hydrogen, lower alkyl or arylalkyl;X is hydrogen, lower alkyl or phenyl;Y is hydrogen, lower alkyl, phenyl or alkoxy, or together X and Y are --(CH.sub.2).sub.2 --, --(CH.sub.2).sub.3 --, --CH.dbd.CH--, or ##STR2## and n is 0 or 1including salts thereof and stereoisomers thereof, which method includes the steps of reacting a phosphinic acid ester of the structure ##STR3## wherein R.sub.

Abstract: Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents are provided which have the structure ##STR1## Z is --(CH.sub.2).sub.n -- or --(CH.sub.2).sub.p --CH.dbd.CH--(CH.sub.2).sub.m --, wherein n is 1 to 5; p is 0, 1 or 2; m is 0, 1 or 2;R, R.sup.1 and R.sup.1a are the same or different and are H, lower alkyl or a metal ion; andR.sup.2 and R.sup.3 may be the same or different and are H or halogen.New intermediates used in preparing the above compounds and method for preparing same, pharmaceutical compositions containing such compounds and a method for using such compounds to inhibit cholesterol biosynthesis are also provided.

Abstract: Boronic acid adducts of radioactive isotopes of rhenium dioxime complexes are useful for labeling biologically active compounds as agents for radiotherapy. These boronic acid adducts of radioactive isotopes of rhenium dioxime complexes have the formulaI. ReX(Y).sub.3 Z,whereinX is an anion;Y is a vicinal dioxime having the formulaII. ##STR1## or a pharmaceutically acceptable salt thereof, and R.sub.1 and R.sub.2 are each independently hydrogen, halogen, alkyl, aryl, amino or a 5 or 6-membered nitrogen or oxygen containing heterocycle, or together R.sub.1 and R.sub.2 are --CR.sub.8 R.sub.9).sub.n --wherein n is 3, 4, 5 or 6 and R.sub.8 and R.sub.9 are each independently hydrogen or alkyl;Z is a boron derivative having the formulaIII. B--R.sub.3wherein R.sub.3 is hydroxy, alkyl, alkenyl, cycloalkyl, cycloaLkenyl, alkoxy, carboxyalkyl, carboxyalkenyl, hydroxyalkyl, hydroxyalkenyl, alkoxyalkyl, alkoxyalkenyl, haloalkyl, haloalkenyl, aryl, arylalkyl or (R.sub.4 R.sub.5 N)-alkyl and R.sub.4 and R.sub.

Abstract: Antibacterial activity is exhibited by 2-azetidinones having a 3-acylamino substituent and having an activating group in the 1-position of the formula ##STR1## wherein R.sub.4 is ##STR2## wherein A.sub.1 is a single bond, ##STR3## --NH-- or ##STR4## A.sub.2 is a single bond, --NH--, --CH.sub.2 --CH.sub.2 --NH-- or ##STR5## A.sub.3 is a single bond, --CH.dbd.CH--, --(CH.sub.2).sub.t --, --NH--(CH.sub.2).sub.p -- or ##STR6## wherein t is 1, 2, 3 or 4 and p is 0 or 1; and A.sub.4 is a single bond --CH.sub.2 --, --NH--CH.sub.2 --, or --N.dbd.CH--.

Abstract: Cardiovascular activity is exhibited by compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sub.1 is ##STR2## or ##STR3## and R.sub.2, R.sub.3 and R.sub.4 are as defined herein.

Abstract: Vasodilating activity is exhibited by compounds having the formula ##STR1## n is 2 or 3; X is oxygen or sulfur,R.sub.1 and R.sub.2 are each independently hydrogen alkyl, cycloalkyl, or allyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl, or morpholinyl;R.sub.3 is alkyl, alkoxy, halogen, trifluoromethyl, or nitro;R.sub.4 is hydrogen, halogen, trifluoromethyl, or nitro; andR.sub.5 and R.sub.6 are each independently alkyl or cycloalkyl or R.sub.5 and R.sub.6 together with the nitrogen atom to which they are attached are pyrrolidinyl, piperidinyl, or morpholinyl.

Abstract: Compounds of the formula ##STR1## wherein X is various amino or imino acids and esters are disclosed. These compounds are useful due to their angiotensin converting enzyme inhibition activity and depending upon the definition of X may also be useful as analgesics due to their enkephalinase inhibition activity.

Abstract: A method is provided for inhibiting onset of or treating migraine headache by administering an ACE inhibitor, such as captopril, alone or in combination with a calcium channel blocker such as diltiazem or nifedipine, over a prolonged period of treatment.